Legacy Ventures Reports Worsening Financials Amid Biotech Aspirations and Rising Losses

Legacy Ventures International, Inc. (PINK: LGYV) released its quarterly report for the period ending December 31, 2024. Currently, the company is focused on general and administrative expenditures, while planning to engage in biotech and healthcare research through its wholly owned subsidiary incorporated in Hong Kong.

Key Financial Highlights:

• Cash Position: Cash as of December 31, 2024, is $983, up from $842 on June 30, 2024.
• Total Assets: Remained flat at $983 since June 30, 2024.
• Total Liabilities: Increased to $182,045 from $137,711, reflecting rising obligations.
• Stockholder's Deficiency: Expanded to $(181,062) from $(136,869) indicating a worsening financial position.

Income Statement Insights:

• Net Loss: For the three months ended December 31, 2024, net loss was $(23,722), compared to $(10,768) in Q4 2023, marking a significant deterioration.
• Operating Expenses: Increased to $23,723 for Q4 2024 from $10,768 in Q4 2023, driven by professional fees.
• Additional Expenses: Other general and administrative expenses increased slightly, reflecting ongoing operational costs.
• Net Loss Per Share: Remained consistent at $(0.00) reflecting the unchanged share count of 50,315,064.

Positive Aspects:

• Minor increase in cash balance provides slight liquidity improvement.
• Continued stakeholder support illustrated by advances from shareholders totaling $61,994 for the six-month period.

Negative Aspects:

• Ongoing net losses cast doubt on the company's ability to continue as a going concern, as indicated by increased accumulated deficit to $(6,615,865).
• Rising operating expenses without revenue generation reflect significant financial strain.
• Dependence on shareholder advances poses risk if further funding is not secured.

Outlook:

Legacy Ventures International is at a critical juncture as its ongoing operations are unsustainable without enhancing revenue streams or securing additional financing. Investors should monitor the company closely for developments regarding its plans in the biotech field and any forthcoming financial support.